September 22, 2025

Acute Cystitis May Signal Urogenital Cancer

Acute cystitis signaled the presence of urogenital cancers in middle-aged men and women, according to the results of a Swedish cohort study published in BMJ Public Health. Based on these findings, the...

The ASCO Post

July 11, 2024

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

A recent cohort study found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the dise...

The ASCO Post

April 10, 2024

Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations

Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study...

The ASCO Post

April 10, 2024

Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations

Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study...

The ASCO Post

March 05, 2024

Metastatic Castration-Resistant Prostate Cancer: Tumor Mutational Burden and Response to Checkpoint Inhibition

Is high tumor mutational burden associated with better outcomes of checkpoint inhibition in patients with metastatic castration-resistant prostate cancer? A recent single-center retrospective study in...

The ASCO Post

February 07, 2024

Insufficiencies Discovered in Patient-Reported Outcomes Data From Genitourinary Cancer Clinical Trials

Investigators assessed whether patient-reported outcomes data are adequately analyzed and reported in genitourinary cancer clinical trials.

The ASCO Post

February 07, 2024

Insufficiencies Discovered in Patient-Reported Outcomes Data From Genitourinary Cancer Clinical Trials

Investigators assessed whether patient-reported outcomes data are adequately analyzed and reported in genitourinary cancer clinical trials.

The ASCO Post

January 30, 2024

Subcutaneous vs Intravenous Nivolumab in Advanced Clear Cell RCC

In previously treated patients with advanced or metastatic clear cell renal cell carcinoma, a subcutaneous formulation of nivolumab was noninferior to the intravenous formulation, according to results...

The ASCO Post

August 18, 2023

Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer

Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disea...

The ASCO Post

April 07, 2023

Highlights of Novel Therapies Under Study in Genitourinary Cancers

Here are some brief reports from the 2023 ASCO Genitourinary (GU) Cancers Symposium that we hope are of interest. They include real-world evidence about the use of avelumab maintenance in metastatic u...

The ASCO Post